Title |
MicroRNA-7: a promising new target in cancer therapy
|
---|---|
Published in |
Cancer Cell International, October 2015
|
DOI | 10.1186/s12935-015-0259-0 |
Pubmed ID | |
Authors |
Juanjuan Zhao, Yijing Tao, Ya Zhou, Nalin Qin, Chao Chen, Dan Tian, Lin Xu |
Abstract |
The incidence of tumors with life-threatening effects has increased gradually over time; however, the mechanisms involved in tumor development have not been fully elucidated. Recent studies have shown that microRNA-7 (miR-7), which is endogenous non-coding RNA molecules of approximately 23 nucleotides, plays an important role in the occurrence and development of tumors as a key tumor suppressor. Mechanistic evidence showed that miR-7 is closely related to the growth, metastasis, and prognosis of various malignant tumors through regulating different target molecules, which suggest that miR-7 may be a new target for the clinical diagnosis and treatment of various tumors. In this review, we summarize current knowledge of the relationship between miR-7 and tumor development, diagnosis, and treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
India | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 1% |
Portugal | 1 | 1% |
Ghana | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 93 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 24 | 25% |
Student > Master | 15 | 15% |
Student > Bachelor | 10 | 10% |
Researcher | 10 | 10% |
Student > Doctoral Student | 8 | 8% |
Other | 10 | 10% |
Unknown | 20 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 31 | 32% |
Agricultural and Biological Sciences | 21 | 22% |
Medicine and Dentistry | 9 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Immunology and Microbiology | 3 | 3% |
Other | 9 | 9% |
Unknown | 21 | 22% |